LA MARCA, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.077
AS - Asia 12.536
EU - Europa 9.561
SA - Sud America 2.060
AF - Africa 309
OC - Oceania 81
Continente sconosciuto - Info sul continente non disponibili 18
Totale 52.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.675
SG - Singapore 4.273
GB - Regno Unito 2.781
CN - Cina 2.720
HK - Hong Kong 1.935
BR - Brasile 1.593
VN - Vietnam 1.513
IT - Italia 1.464
SE - Svezia 1.121
DE - Germania 876
FI - Finlandia 790
UA - Ucraina 593
RU - Federazione Russa 510
TR - Turchia 423
FR - Francia 400
IN - India 283
KR - Corea 250
BG - Bulgaria 243
CA - Canada 195
AR - Argentina 175
ID - Indonesia 169
BD - Bangladesh 152
NL - Olanda 151
JP - Giappone 130
MX - Messico 129
IQ - Iraq 111
ES - Italia 110
ZA - Sudafrica 83
EC - Ecuador 69
PK - Pakistan 68
RO - Romania 64
AU - Australia 61
PL - Polonia 61
PH - Filippine 59
AE - Emirati Arabi Uniti 58
CO - Colombia 55
IR - Iran 51
IE - Irlanda 48
CL - Cile 46
VE - Venezuela 46
UZ - Uzbekistan 45
DZ - Algeria 42
MA - Marocco 42
MY - Malesia 41
LT - Lituania 37
CH - Svizzera 36
BE - Belgio 35
DK - Danimarca 35
CZ - Repubblica Ceca 33
AT - Austria 32
KE - Kenya 32
EG - Egitto 30
PY - Paraguay 29
TW - Taiwan 27
TH - Thailandia 26
JO - Giordania 24
SA - Arabia Saudita 24
NP - Nepal 23
TN - Tunisia 20
AL - Albania 19
DO - Repubblica Dominicana 17
NZ - Nuova Zelanda 17
PE - Perù 17
AZ - Azerbaigian 16
BO - Bolivia 16
KZ - Kazakistan 16
HR - Croazia 15
IL - Israele 15
NG - Nigeria 15
CR - Costa Rica 14
NO - Norvegia 14
JM - Giamaica 12
MD - Moldavia 12
PS - Palestinian Territory 12
PT - Portogallo 11
GR - Grecia 10
HU - Ungheria 10
LV - Lettonia 10
UY - Uruguay 10
PA - Panama 9
ET - Etiopia 8
OM - Oman 8
SI - Slovenia 8
SK - Slovacchia (Repubblica Slovacca) 8
EU - Europa 7
GH - Ghana 7
HN - Honduras 7
QA - Qatar 7
BA - Bosnia-Erzegovina 6
KW - Kuwait 6
LB - Libano 6
SN - Senegal 6
XK - ???statistics.table.value.countryCode.XK??? 6
AM - Armenia 5
GT - Guatemala 5
MN - Mongolia 5
RS - Serbia 5
SC - Seychelles 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
Totale 52.558
Salva come PNG Salva come JPEG
Città #
Fairfield 3.903
Ashburn 2.865
Singapore 2.692
Santa Clara 2.273
Hong Kong 1.891
Woodbridge 1.886
Southend 1.737
Houston 1.577
Seattle 1.473
Cambridge 1.304
Wilmington 1.172
Chandler 1.125
Jacksonville 901
Ann Arbor 758
Dearborn 681
Helsinki 679
Nyköping 675
Beijing 621
London 617
Hefei 590
San Jose 581
Ho Chi Minh City 487
Modena 390
The Dalles 375
Los Angeles 351
Chicago 348
Hanoi 335
San Diego 289
Council Bluffs 276
Princeton 237
Sofia 234
New York 227
Seoul 209
Izmir 207
Lauterbourg 194
Eugene 193
Moscow 185
Boardman 163
São Paulo 140
Shanghai 135
Buffalo 132
Bremen 119
Jakarta 111
Salt Lake City 111
Dallas 107
Milan 96
Tokyo 88
Munich 87
Guangzhou 85
Rome 79
Frankfurt am Main 77
Da Nang 72
Redwood City 68
Tampa 68
Redondo Beach 65
Haiphong 64
Amsterdam 62
Bologna 61
Columbus 58
Orem 57
Vancouver 55
Rio de Janeiro 50
Phoenix 48
Toronto 45
Baghdad 44
Dublin 43
Elk Grove Village 43
Johannesburg 43
Atlanta 41
Chennai 40
Falls Church 40
Warsaw 40
Tashkent 39
Biên Hòa 38
Denver 38
Mexico City 37
Montreal 37
Norwalk 37
Stockholm 35
Kilburn 34
Nanjing 34
Melbourne 33
Fremont 32
Belo Horizonte 31
Brooklyn 31
Iasi 31
Ankara 30
Brasília 29
Mumbai 29
San Francisco 29
Kunming 28
Porto Alegre 28
Turku 27
Nairobi 26
Paris 26
Boston 25
Jinan 25
Manchester 25
Amman 24
Curitiba 24
Totale 38.037
Salva come PNG Salva come JPEG
Nome #
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial 609
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 472
Anti-Mullerian hormone (AMH): what do we still need to know? 468
Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome 420
MATER protein as substrate of PKCepsilon in human cumulus cells. 412
LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling 399
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice 373
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach 358
Age-specific nomogram for the decline in antral follicle count throughout the reproductive period 342
Embryo quality and implantation rate in two different culture media: ISM1 versus Universal IVF Medium. 341
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 330
From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology 328
Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period 327
The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH 326
The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study 325
Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium 324
How Much Does AMH Really Vary in Normal Women? 322
Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? 321
FSHR polymorphism p.N680S mediates different responses to FSH in vitro 321
A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos 318
Vitamin D and ovarian reserve: making clinical decisions 317
Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles 314
Human ovarian tissue cryopreservation: effect of sucrose concentration on morphological features after thawing 313
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol 313
Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology 310
Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH) 310
Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period 309
Adnexal torsion during pregnancy after oocyte in vitro maturation and intracytoplasmic sperminjection cycle 308
Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles 308
Elevated levels of nitrous dioxide are associated with lower AMH levels: A real-world analysis 298
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization 297
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium 297
Periodontal disease and nitric oxide levels in low risk women with preterm labor 296
Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study 295
Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count 288
Primary ovarian insufficiency: autoimmune causes. 285
The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro 285
A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles 285
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria 284
New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation 284
Nitric Oxide concentration in endometrial washing throughout the menstrual cycle 283
The physiology and clinical utility of anti-Mullerian hormone in women 282
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. 277
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 277
Administration of L-thyroxine does not improve the response of the hypothalamo-pituitary-ovarian axis to clomiphene citrate in functional hypothalamic amenorrhea 276
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study 272
The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause 272
Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele 270
Anti-Mullerian hormone concentrations in maternal serum during pregnancy 268
Utero-vaginal anastomosis in the treatment of cervical atresia 268
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome 268
Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome? 267
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction 264
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 264
Pregnant woman infected by Coronavirus disease (COVID-19) and calcifications of the fetal bowel and gallbladder 264
Adrenal adenocarcinoma and empty sella syndrome in a 37-year-old woman 263
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 256
Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes 256
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history 256
How to personalize ovarian stimulation in clinical practice 255
The management of vaginal agenesis: report of 104 cases 255
Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata 254
Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause 253
Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in PCOS patients 252
Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome 251
The use of ovarian reserve markers in IVF clinical practice: a national consensus 250
Rectovaginal fistula repair using fascia graft of autologous abdominal muscles 250
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction 249
The ovarian follicular pool and reproductive outcome in women. 249
The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age 248
Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: An individual patient data meta-analysis 248
Metformin treatment of PCOS during adolescence and the reproductive period 247
8th World Congress of Gynecological Endocrinology 247
The FSHR polymorphism p.N680S mediates different response kinetics to FSH in vitro 247
Rectus abdominis muscle endometriosis: Case report and review of the literature 242
Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study 242
Reply: The two sides of the individualization of controlled ovarian stimulation 241
External validation of anti-Müllerian hormone based prediction of live birth in assisted conception 237
Soluble L-selectin levels during controlled ovarian hyperstimulation 237
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) 235
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia 233
Thyroid function in early pregnancy II: Paradoxical growth hormone response to thyrotropin-releasing hormone 233
Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency 233
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women 233
Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply 232
Surgical treatment of ovarian dermoid cysts 232
Hormonal and ultrasound markers of ovarian function in a woman with a balanced 1;11 translocation 231
The journey from the old to the new AMH assay: how to avoid getting lost in the values 231
Anti-Müllerian hormone: clairvoyance or crystal clear? 231
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium 231
Clinical, endocrine and metabolic effects of acarbose, an α-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance 230
Serum anti-Mullerian hormone throughout the human menstrual cycle 229
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome 229
Evaluation of plasma levels of renin-aldosterone and blood pressure in women over 35 years treated with new oral contraceptives 229
Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy 228
Recombinant human leptin in women with hypothalamic amenorrhea. 227
Pyrexia, leukocytosis and elevated circulating platelets associated to uterine stromal sarcoma with rhabdoid differentiation 227
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome 227
Serum anti-mullerian hormone levels in women with secondary amenorrhea 225
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients 223
Totale 28.318
Salva come PNG Salva come JPEG
Categoria #
all - tutte 209.761
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 209.761
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.325 0 0 0 0 0 0 0 0 0 699 353 273
2021/20224.566 176 862 513 160 84 175 345 216 415 356 872 392
2022/20233.625 454 416 349 293 473 434 82 308 414 39 174 189
2023/20243.007 95 153 122 270 479 180 510 456 68 95 131 448
2024/20258.209 260 89 107 581 1.510 1.099 434 449 1.158 519 786 1.217
2025/202615.707 1.057 530 1.581 2.000 2.208 1.427 2.410 1.109 1.884 1.501 0 0
Totale 53.079